(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-1.04%) $82.98
(-1.16%) $1.619
(-0.46%) $2 336.40
(-0.53%) $27.39
(0.35%) $925.30
(-0.11%) $0.934
(-0.09%) $11.02
(-0.19%) $0.799
(0.00%) $92.17
2 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 5.40%
@ $0.976
発行日: 8 2月 2024 @ 05:19
リターン: 29.12%
前回のシグナル: 2月 8 - 03:02
前回のシグナル:
リターン: -0.80 %
Live Chart Being Loaded With Signals
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally...
Stats | |
---|---|
本日の出来高 | 1.85M |
平均出来高 | 8.91M |
時価総額 | 878.21M |
EPS | $0 ( 2024-02-27 ) |
次の収益日 | ( $-0.0900 ) 2024-05-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -5.04 |
ATR14 | $0.00700 (0.56%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-28 | Yu Alice Lin-tsing | Buy | 0 | |
2024-03-28 | Paganelli John A | Buy | 0 | |
2024-03-28 | Lachman Prem A | Buy | 0 | |
2024-03-28 | Pfenniger Richard C Jr | Buy | 0 | |
2024-03-28 | Krasno Richard M | Buy | 0 |
INSIDER POWER |
---|
100.00 |
Last 94 transactions |
Buy: 12 318 025 | Sell: 0 |
ボリューム 相関
OPKO Health Inc 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
OPKO Health Inc 相関 - 通貨/商品
OPKO Health Inc 財務諸表
Annual | 2023 |
収益: | $863.50M |
総利益: | $232.10M (26.88 %) |
EPS: | $-0.250 |
FY | 2023 |
収益: | $863.50M |
総利益: | $232.10M (26.88 %) |
EPS: | $-0.250 |
FY | 2022 |
収益: | $1.00B |
総利益: | $288.20M (28.70 %) |
EPS: | $-0.460 |
FY | 2021 |
収益: | $1.77B |
総利益: | $581.52M (32.77 %) |
EPS: | $-0.0500 |
Financial Reports:
No articles found.
OPKO Health Inc
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。